You are here

antivirals

FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults

FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults

CNBC

Flag link:

Biotech launched during Covid — for Covid — looks for strategic alternatives after antiviral fails PhII trial

Biotech launched during Covid — for Covid — looks for strategic alternatives after antiviral fails PhII trial

Endpoints

Pardes Biosciences

Flag link:

FDA adcomm votes in favor of Pfizer's Covid-19 pill Paxlovid

FDA adcomm votes in favor of Pfizer's Covid-19 pill Paxlovid

Endpoints

Flag link:

FDA staff report says data shows Pfizer’s Covid treatment Paxlovid is effective in high-risk adults

FDA staff report says data shows Pfizer’s Covid treatment Paxlovid is effective in high-risk adults

CNBC

Flag link:

Merck asks EMA to reevaluate rejected Covid-19 antiviral

Merck asks EMA to reevaluate rejected Covid-19 antiviral

Endpoints

Flag link:

Merck pill linked to new mutations, study says

Merck pill linked to new mutations, study says

Fierce Pharma

Flag link:

Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program

Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program

Fierce Biotech

Gilead Sciences

Matinas BioPharma

Flag link:

Pfizer's search for Paxlovid's COVID-busting sibling leads to low-profile antiviral biotech

Pfizer's search for Paxlovid's COVID-busting sibling leads to low-profile antiviral biotech

Fierce Biotech

Flag link:

Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck

Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck

Fierce Pharma

Flag link:

FDA Cites ‘Uncertainties’ in Veru's COVID-19 Antiviral Data Ahead of Adcomm

FDA Cites ‘Uncertainties’ in Veru's COVID-19 Antiviral Data Ahead of Adcomm

BioSpace

Flag link:

FDA chief stands by Paxlovid nod amid discussion on 'rebound' cases

FDA chief stands by Paxlovid nod amid discussion on 'rebound' cases

Fierce Pharma

Flag link:

Siga nabs $10.7M from the US government in deal for its monkeypox antiviral

Siga nabs $10.7M from the US government in deal for its monkeypox antiviral

Endpoints

SIGA technologies

Flag link:

Emergent wraps up purchase of Chimerix's potential monkeypox treatment Tembexa

Emergent wraps up purchase of Chimerix's potential monkeypox treatment Tembexa

Fierce Pharma

Emergent BioSolutions

Flag link:

Pardes initiates Phase II trial of Covid-19 antiviral drug

Pardes initiates Phase II trial of Covid-19 antiviral drug

Clinical Trials Arena

Pardes Biosciences

Flag link:

US earmarks up to $680M for Chimerix’s smallpox drug Tembexa, clearing way for Emergent buyout

US earmarks up to $680M for Chimerix’s smallpox drug Tembexa, clearing way for Emergent buyout

Fierce Pharma

government contract

Flag link:

Multiple monkeypox vaccine and antiviral trials are launching across the world

Multiple monkeypox vaccine and antiviral trials are launching across the world

Clinical Trials Arena

clinical trials

Bavarian Nordic

SIGA technologies

Flag link:

Feud between two biotechs left nearly 12M doses of monkeypox antiviral on the table

Feud between two biotechs left nearly 12M doses of monkeypox antiviral on the table

Endpoints

SIGA technologies

Flag link:

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

BioSpace

drug development

Flag link:

Pfizer's Paxlovid sales will top at $30B this year then fall over time: analysts

Pfizer's Paxlovid sales will top at $30B this year then fall over time: analysts

Fierce Pharma

Flag link:

Staffing shortage could be hindering controversial Paxlovid clearance

Staffing shortage could be hindering controversial Paxlovid clearance

Beckers Hospital Review

Flag link:

Pages